nodes	percent_of_prediction	percent_of_DWPC	metapath
Vorinostat—NR0B1—Dexamethasone—ankylosing spondylitis	0.815	1	CbGbCtD
Vorinostat—Gastrointestinal toxicity—Methotrexate—ankylosing spondylitis	0.00557	0.0375	CcSEcCtD
Vorinostat—Ureteric obstruction—Methotrexate—ankylosing spondylitis	0.00557	0.0375	CcSEcCtD
Vorinostat—Thromboembolism—Prednisolone—ankylosing spondylitis	0.00474	0.0319	CcSEcCtD
Vorinostat—Thromboembolism—Triamcinolone—ankylosing spondylitis	0.00436	0.0293	CcSEcCtD
Vorinostat—Thromboembolism—Methylprednisolone—ankylosing spondylitis	0.00435	0.0292	CcSEcCtD
Vorinostat—Thromboembolism—Dexamethasone—ankylosing spondylitis	0.00395	0.0266	CcSEcCtD
Vorinostat—Thromboembolism—Betamethasone—ankylosing spondylitis	0.00395	0.0266	CcSEcCtD
Vorinostat—Thromboembolism—Prednisone—ankylosing spondylitis	0.00344	0.0231	CcSEcCtD
Vorinostat—HDAC4—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00314	0.0873	CbGpPWpGaD
Vorinostat—Embolism venous—Prednisolone—ankylosing spondylitis	0.00299	0.0201	CcSEcCtD
Vorinostat—Embolism venous—Triamcinolone—ankylosing spondylitis	0.00275	0.0185	CcSEcCtD
Vorinostat—Embolism venous—Methylprednisolone—ankylosing spondylitis	0.00274	0.0184	CcSEcCtD
Vorinostat—Embolism venous—Dexamethasone—ankylosing spondylitis	0.00249	0.0167	CcSEcCtD
Vorinostat—Embolism venous—Betamethasone—ankylosing spondylitis	0.00249	0.0167	CcSEcCtD
Vorinostat—Embolism—Prednisolone—ankylosing spondylitis	0.00235	0.0158	CcSEcCtD
Vorinostat—Embolism venous—Prednisone—ankylosing spondylitis	0.00217	0.0146	CcSEcCtD
Vorinostat—Embolism—Triamcinolone—ankylosing spondylitis	0.00216	0.0145	CcSEcCtD
Vorinostat—Embolism—Methylprednisolone—ankylosing spondylitis	0.00215	0.0145	CcSEcCtD
Vorinostat—Embolism—Dexamethasone—ankylosing spondylitis	0.00196	0.0132	CcSEcCtD
Vorinostat—Embolism—Betamethasone—ankylosing spondylitis	0.00196	0.0132	CcSEcCtD
Vorinostat—Abscess—Prednisolone—ankylosing spondylitis	0.0019	0.0128	CcSEcCtD
Vorinostat—NCOR1—Regulation of nuclear SMAD2/3 signaling—RUNX3—ankylosing spondylitis	0.00185	0.0515	CbGpPWpGaD
Vorinostat—Abscess—Triamcinolone—ankylosing spondylitis	0.00175	0.0118	CcSEcCtD
Vorinostat—Abscess—Methylprednisolone—ankylosing spondylitis	0.00175	0.0117	CcSEcCtD
Vorinostat—Embolism—Prednisone—ankylosing spondylitis	0.00171	0.0115	CcSEcCtD
Vorinostat—Abscess—Betamethasone—ankylosing spondylitis	0.00159	0.0107	CcSEcCtD
Vorinostat—Abscess—Dexamethasone—ankylosing spondylitis	0.00159	0.0107	CcSEcCtD
Vorinostat—HDAC1—Regulation of nuclear SMAD2/3 signaling—RUNX3—ankylosing spondylitis	0.00151	0.042	CbGpPWpGaD
Vorinostat—Deep vein thrombosis—Methotrexate—ankylosing spondylitis	0.0015	0.0101	CcSEcCtD
Vorinostat—Embolism—Methotrexate—ankylosing spondylitis	0.00143	0.00958	CcSEcCtD
Vorinostat—Abscess—Prednisone—ankylosing spondylitis	0.00138	0.0093	CcSEcCtD
Vorinostat—HDAC9—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.00133	0.0369	CbGpPWpGaD
Vorinostat—Abscess—Methotrexate—ankylosing spondylitis	0.00116	0.00777	CcSEcCtD
Vorinostat—Proteinuria—Methotrexate—ankylosing spondylitis	0.00104	0.007	CcSEcCtD
Vorinostat—HDAC1—IL-6 signaling pathway—CRP—ankylosing spondylitis	0.00104	0.0289	CbGpPWpGaD
Vorinostat—Protein urine present—Methotrexate—ankylosing spondylitis	0.00103	0.0069	CcSEcCtD
Vorinostat—HDAC2—Regulation of nuclear SMAD2/3 signaling—RUNX3—ankylosing spondylitis	0.000973	0.0271	CbGpPWpGaD
Vorinostat—Sepsis—Prednisone—ankylosing spondylitis	0.00095	0.00639	CcSEcCtD
Vorinostat—Lethargy—Dexamethasone—ankylosing spondylitis	0.000931	0.00626	CcSEcCtD
Vorinostat—Lethargy—Betamethasone—ankylosing spondylitis	0.000931	0.00626	CcSEcCtD
Vorinostat—HDAC9—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000917	0.0255	CbGpPWpGaD
Vorinostat—Pulmonary embolism—Methotrexate—ankylosing spondylitis	0.000915	0.00615	CcSEcCtD
Vorinostat—NCOR1—Regulation of nuclear SMAD2/3 signaling—IL10—ankylosing spondylitis	0.000915	0.0254	CbGpPWpGaD
Vorinostat—HDAC1—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000894	0.0249	CbGpPWpGaD
Vorinostat—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.000831	0.00559	CcSEcCtD
Vorinostat—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.00083	0.00558	CcSEcCtD
Vorinostat—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.00083	0.00558	CcSEcCtD
Vorinostat—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.000826	0.00555	CcSEcCtD
Vorinostat—Lethargy—Prednisone—ankylosing spondylitis	0.000811	0.00545	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.000808	0.00543	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Prednisone—ankylosing spondylitis	0.000795	0.00534	CcSEcCtD
Vorinostat—Sepsis—Methotrexate—ankylosing spondylitis	0.000794	0.00534	CcSEcCtD
Vorinostat—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.000764	0.00514	CcSEcCtD
Vorinostat—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.000762	0.00512	CcSEcCtD
Vorinostat—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.00076	0.00511	CcSEcCtD
Vorinostat—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.000758	0.0051	CcSEcCtD
Vorinostat—HDAC1—Regulation of nuclear SMAD2/3 signaling—IL10—ankylosing spondylitis	0.000746	0.0207	CbGpPWpGaD
Vorinostat—HDAC11—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000725	0.0201	CbGpPWpGaD
Vorinostat—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000723	0.00486	CcSEcCtD
Vorinostat—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000713	0.0048	CcSEcCtD
Vorinostat—Weight decreased—Betamethasone—ankylosing spondylitis	0.000713	0.0048	CcSEcCtD
Vorinostat—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.000711	0.00478	CcSEcCtD
Vorinostat—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.000711	0.00478	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.000704	0.00473	CcSEcCtD
Vorinostat—HDAC11—Disease—ANTXR2—ankylosing spondylitis	0.0007	0.0195	CbGpPWpGaD
Vorinostat—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.000693	0.00466	CcSEcCtD
Vorinostat—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.000693	0.00466	CcSEcCtD
Vorinostat—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.000689	0.00463	CcSEcCtD
Vorinostat—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.000689	0.00463	CcSEcCtD
Vorinostat—Lethargy—Methotrexate—ankylosing spondylitis	0.000678	0.00456	CcSEcCtD
Vorinostat—HDAC4—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000666	0.0185	CbGpPWpGaD
Vorinostat—HDAC9—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.00066	0.0183	CbGpPWpGaD
Vorinostat—HDAC9—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000656	0.0182	CbGpPWpGaD
Vorinostat—Neutropenia—Prednisone—ankylosing spondylitis	0.000642	0.00432	CcSEcCtD
Vorinostat—Weight decreased—Prednisone—ankylosing spondylitis	0.000621	0.00418	CcSEcCtD
Vorinostat—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.00062	0.00417	CcSEcCtD
Vorinostat—HDAC1—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000617	0.0172	CbGpPWpGaD
Vorinostat—HDAC6—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000607	0.0169	CbGpPWpGaD
Vorinostat—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000604	0.00406	CcSEcCtD
Vorinostat—Angioedema—Prednisolone—ankylosing spondylitis	0.000602	0.00405	CcSEcCtD
Vorinostat—Myocardial infarction—Prednisone—ankylosing spondylitis	0.0006	0.00404	CcSEcCtD
Vorinostat—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000593	0.00399	CcSEcCtD
Vorinostat—Syncope—Prednisolone—ankylosing spondylitis	0.000591	0.00397	CcSEcCtD
Vorinostat—HDAC6—Disease—ANTXR2—ankylosing spondylitis	0.000586	0.0163	CbGpPWpGaD
Vorinostat—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000579	0.00389	CcSEcCtD
Vorinostat—HDAC9—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000575	0.016	CbGpPWpGaD
Vorinostat—Alopecia—Betamethasone—ankylosing spondylitis	0.000558	0.00375	CcSEcCtD
Vorinostat—Alopecia—Dexamethasone—ankylosing spondylitis	0.000558	0.00375	CcSEcCtD
Vorinostat—HDAC6—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000555	0.0154	CbGpPWpGaD
Vorinostat—Angioedema—Triamcinolone—ankylosing spondylitis	0.000553	0.00372	CcSEcCtD
Vorinostat—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000552	0.00371	CcSEcCtD
Vorinostat—HDAC4—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000549	0.0153	CbGpPWpGaD
Vorinostat—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000545	0.00366	CcSEcCtD
Vorinostat—Syncope—Triamcinolone—ankylosing spondylitis	0.000543	0.00365	CcSEcCtD
Vorinostat—Syncope—Methylprednisolone—ankylosing spondylitis	0.000542	0.00364	CcSEcCtD
Vorinostat—Neutropenia—Methotrexate—ankylosing spondylitis	0.000537	0.00361	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000533	0.00359	CcSEcCtD
Vorinostat—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000532	0.00358	CcSEcCtD
Vorinostat—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000531	0.00357	CcSEcCtD
Vorinostat—HDAC4—Disease—ANTXR2—ankylosing spondylitis	0.00053	0.0147	CbGpPWpGaD
Vorinostat—Shock—Prednisolone—ankylosing spondylitis	0.000529	0.00356	CcSEcCtD
Vorinostat—Cough—Triamcinolone—ankylosing spondylitis	0.000528	0.00355	CcSEcCtD
Vorinostat—HDAC8—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000507	0.0141	CbGpPWpGaD
Vorinostat—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000504	0.00339	CcSEcCtD
Vorinostat—Angioedema—Dexamethasone—ankylosing spondylitis	0.000502	0.00338	CcSEcCtD
Vorinostat—Angioedema—Betamethasone—ankylosing spondylitis	0.000502	0.00338	CcSEcCtD
Vorinostat—Syncope—Betamethasone—ankylosing spondylitis	0.000493	0.00331	CcSEcCtD
Vorinostat—Syncope—Dexamethasone—ankylosing spondylitis	0.000493	0.00331	CcSEcCtD
Vorinostat—Infection—Triamcinolone—ankylosing spondylitis	0.000491	0.0033	CcSEcCtD
Vorinostat—Infection—Methylprednisolone—ankylosing spondylitis	0.00049	0.00329	CcSEcCtD
Vorinostat—HDAC8—Disease—ANTXR2—ankylosing spondylitis	0.000489	0.0136	CbGpPWpGaD
Vorinostat—Shock—Triamcinolone—ankylosing spondylitis	0.000486	0.00327	CcSEcCtD
Vorinostat—Alopecia—Prednisone—ankylosing spondylitis	0.000486	0.00327	CcSEcCtD
Vorinostat—Shock—Methylprednisolone—ankylosing spondylitis	0.000485	0.00326	CcSEcCtD
Vorinostat—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000483	0.00325	CcSEcCtD
Vorinostat—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000483	0.00325	CcSEcCtD
Vorinostat—HDAC2—Regulation of nuclear SMAD2/3 signaling—IL10—ankylosing spondylitis	0.00048	0.0134	CbGpPWpGaD
Vorinostat—HDAC1—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.00048	0.0133	CbGpPWpGaD
Vorinostat—HDAC4—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000475	0.0132	CbGpPWpGaD
Vorinostat—HDAC9—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000474	0.0132	CbGpPWpGaD
Vorinostat—HDAC9—Disease—ANTXR2—ankylosing spondylitis	0.000458	0.0127	CbGpPWpGaD
Vorinostat—Infection—Dexamethasone—ankylosing spondylitis	0.000446	0.003	CcSEcCtD
Vorinostat—Infection—Betamethasone—ankylosing spondylitis	0.000446	0.003	CcSEcCtD
Vorinostat—HDAC1—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000444	0.0123	CbGpPWpGaD
Vorinostat—Anaemia—Prednisone—ankylosing spondylitis	0.000442	0.00297	CcSEcCtD
Vorinostat—HDAC1—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000441	0.0123	CbGpPWpGaD
Vorinostat—Shock—Dexamethasone—ankylosing spondylitis	0.000441	0.00297	CcSEcCtD
Vorinostat—Shock—Betamethasone—ankylosing spondylitis	0.000441	0.00297	CcSEcCtD
Vorinostat—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000439	0.00295	CcSEcCtD
Vorinostat—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000439	0.00295	CcSEcCtD
Vorinostat—Angioedema—Prednisone—ankylosing spondylitis	0.000437	0.00294	CcSEcCtD
Vorinostat—Syncope—Prednisone—ankylosing spondylitis	0.000429	0.00289	CcSEcCtD
Vorinostat—Anorexia—Betamethasone—ankylosing spondylitis	0.000427	0.00287	CcSEcCtD
Vorinostat—Anorexia—Dexamethasone—ankylosing spondylitis	0.000427	0.00287	CcSEcCtD
Vorinostat—Fatigue—Triamcinolone—ankylosing spondylitis	0.000426	0.00287	CcSEcCtD
Vorinostat—HDAC3—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000426	0.0118	CbGpPWpGaD
Vorinostat—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000425	0.00286	CcSEcCtD
Vorinostat—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000421	0.00283	CcSEcCtD
Vorinostat—HDAC11—Disease—B3GNT2—ankylosing spondylitis	0.000412	0.0115	CbGpPWpGaD
Vorinostat—Chills—Methotrexate—ankylosing spondylitis	0.000412	0.00277	CcSEcCtD
Vorinostat—HDAC3—Disease—ANTXR2—ankylosing spondylitis	0.000411	0.0114	CbGpPWpGaD
Vorinostat—HDAC9—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.00041	0.0114	CbGpPWpGaD
Vorinostat—Alopecia—Methotrexate—ankylosing spondylitis	0.000406	0.00273	CcSEcCtD
Vorinostat—HDAC1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—ankylosing spondylitis	0.000398	0.0111	CbGpPWpGaD
Vorinostat—HDAC3—Transcriptional regulation of white adipocyte differentiation—TNF—ankylosing spondylitis	0.000394	0.011	CbGpPWpGaD
Vorinostat—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000392	0.00263	CcSEcCtD
Vorinostat—NCOR1—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000391	0.0109	CbGpPWpGaD
Vorinostat—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000391	0.00263	CcSEcCtD
Vorinostat—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00039	0.00262	CcSEcCtD
Vorinostat—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00039	0.00262	CcSEcCtD
Vorinostat—Infection—Prednisone—ankylosing spondylitis	0.000388	0.00261	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000387	0.0026	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000387	0.0026	CcSEcCtD
Vorinostat—Fatigue—Dexamethasone—ankylosing spondylitis	0.000387	0.0026	CcSEcCtD
Vorinostat—Fatigue—Betamethasone—ankylosing spondylitis	0.000387	0.0026	CcSEcCtD
Vorinostat—Shock—Prednisone—ankylosing spondylitis	0.000384	0.00258	CcSEcCtD
Vorinostat—NCOR1—Disease—ANTXR2—ankylosing spondylitis	0.000378	0.0105	CbGpPWpGaD
Vorinostat—Anorexia—Prednisone—ankylosing spondylitis	0.000372	0.0025	CcSEcCtD
Vorinostat—Anaemia—Methotrexate—ankylosing spondylitis	0.00037	0.00249	CcSEcCtD
Vorinostat—NCOR1—Transcriptional regulation of white adipocyte differentiation—TNF—ankylosing spondylitis	0.000363	0.0101	CbGpPWpGaD
Vorinostat—Leukopenia—Methotrexate—ankylosing spondylitis	0.000358	0.00241	CcSEcCtD
Vorinostat—Dizziness—Prednisolone—ankylosing spondylitis	0.000355	0.00239	CcSEcCtD
Vorinostat—Asthenia—Triamcinolone—ankylosing spondylitis	0.000355	0.00238	CcSEcCtD
Vorinostat—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000355	0.00238	CcSEcCtD
Vorinostat—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000355	0.00238	CcSEcCtD
Vorinostat—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000354	0.00238	CcSEcCtD
Vorinostat—Pruritus—Triamcinolone—ankylosing spondylitis	0.00035	0.00235	CcSEcCtD
Vorinostat—Cough—Methotrexate—ankylosing spondylitis	0.000349	0.00235	CcSEcCtD
Vorinostat—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000349	0.00235	CcSEcCtD
Vorinostat—HDAC6—Disease—B3GNT2—ankylosing spondylitis	0.000346	0.00961	CbGpPWpGaD
Vorinostat—Chest pain—Methotrexate—ankylosing spondylitis	0.00034	0.00229	CcSEcCtD
Vorinostat—Decreased appetite—Prednisone—ankylosing spondylitis	0.000339	0.00228	CcSEcCtD
Vorinostat—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000337	0.00227	CcSEcCtD
Vorinostat—Fatigue—Prednisone—ankylosing spondylitis	0.000337	0.00226	CcSEcCtD
Vorinostat—Headache—Prednisolone—ankylosing spondylitis	0.000337	0.00226	CcSEcCtD
Vorinostat—Constipation—Prednisone—ankylosing spondylitis	0.000334	0.00225	CcSEcCtD
Vorinostat—Dizziness—Triamcinolone—ankylosing spondylitis	0.000327	0.0022	CcSEcCtD
Vorinostat—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000326	0.00219	CcSEcCtD
Vorinostat—Infection—Methotrexate—ankylosing spondylitis	0.000324	0.00218	CcSEcCtD
Vorinostat—Asthenia—Dexamethasone—ankylosing spondylitis	0.000322	0.00216	CcSEcCtD
Vorinostat—Asthenia—Betamethasone—ankylosing spondylitis	0.000322	0.00216	CcSEcCtD
Vorinostat—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.00032	0.00215	CcSEcCtD
Vorinostat—Nausea—Prednisolone—ankylosing spondylitis	0.000319	0.00215	CcSEcCtD
Vorinostat—HDAC1—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000319	0.00887	CbGpPWpGaD
Vorinostat—Pruritus—Dexamethasone—ankylosing spondylitis	0.000317	0.00213	CcSEcCtD
Vorinostat—Pruritus—Betamethasone—ankylosing spondylitis	0.000317	0.00213	CcSEcCtD
Vorinostat—Vomiting—Triamcinolone—ankylosing spondylitis	0.000314	0.00211	CcSEcCtD
Vorinostat—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000314	0.00211	CcSEcCtD
Vorinostat—HDAC4—Disease—B3GNT2—ankylosing spondylitis	0.000313	0.00869	CbGpPWpGaD
Vorinostat—Anorexia—Methotrexate—ankylosing spondylitis	0.000311	0.00209	CcSEcCtD
Vorinostat—Headache—Triamcinolone—ankylosing spondylitis	0.00031	0.00208	CcSEcCtD
Vorinostat—Headache—Methylprednisolone—ankylosing spondylitis	0.000309	0.00208	CcSEcCtD
Vorinostat—Body temperature increased—Prednisone—ankylosing spondylitis	0.000309	0.00208	CcSEcCtD
Vorinostat—HDAC1—Disease—ANTXR2—ankylosing spondylitis	0.000308	0.00857	CbGpPWpGaD
Vorinostat—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000307	0.00206	CcSEcCtD
Vorinostat—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000307	0.00206	CcSEcCtD
Vorinostat—Dizziness—Dexamethasone—ankylosing spondylitis	0.000297	0.00199	CcSEcCtD
Vorinostat—Dizziness—Betamethasone—ankylosing spondylitis	0.000297	0.00199	CcSEcCtD
Vorinostat—Nausea—Triamcinolone—ankylosing spondylitis	0.000294	0.00197	CcSEcCtD
Vorinostat—Nausea—Methylprednisolone—ankylosing spondylitis	0.000293	0.00197	CcSEcCtD
Vorinostat—HDAC8—Disease—B3GNT2—ankylosing spondylitis	0.000288	0.00802	CbGpPWpGaD
Vorinostat—Vomiting—Dexamethasone—ankylosing spondylitis	0.000285	0.00192	CcSEcCtD
Vorinostat—Vomiting—Betamethasone—ankylosing spondylitis	0.000285	0.00192	CcSEcCtD
Vorinostat—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000284	0.00191	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000282	0.00189	CcSEcCtD
Vorinostat—Fatigue—Methotrexate—ankylosing spondylitis	0.000281	0.00189	CcSEcCtD
Vorinostat—Headache—Betamethasone—ankylosing spondylitis	0.000281	0.00189	CcSEcCtD
Vorinostat—Headache—Dexamethasone—ankylosing spondylitis	0.000281	0.00189	CcSEcCtD
Vorinostat—Asthenia—Prednisone—ankylosing spondylitis	0.00028	0.00188	CcSEcCtD
Vorinostat—Pruritus—Prednisone—ankylosing spondylitis	0.000276	0.00186	CcSEcCtD
Vorinostat—HDAC9—Disease—B3GNT2—ankylosing spondylitis	0.00027	0.0075	CbGpPWpGaD
Vorinostat—Diarrhoea—Prednisone—ankylosing spondylitis	0.000267	0.0018	CcSEcCtD
Vorinostat—Nausea—Dexamethasone—ankylosing spondylitis	0.000266	0.00179	CcSEcCtD
Vorinostat—Nausea—Betamethasone—ankylosing spondylitis	0.000266	0.00179	CcSEcCtD
Vorinostat—Dizziness—Prednisone—ankylosing spondylitis	0.000258	0.00174	CcSEcCtD
Vorinostat—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000258	0.00173	CcSEcCtD
Vorinostat—HDAC9—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.00025	0.00694	CbGpPWpGaD
Vorinostat—Vomiting—Prednisone—ankylosing spondylitis	0.000248	0.00167	CcSEcCtD
Vorinostat—Headache—Prednisone—ankylosing spondylitis	0.000245	0.00165	CcSEcCtD
Vorinostat—HDAC3—Disease—B3GNT2—ankylosing spondylitis	0.000242	0.00674	CbGpPWpGaD
Vorinostat—NCOR1—Adipogenesis—TNF—ankylosing spondylitis	0.000238	0.00663	CbGpPWpGaD
Vorinostat—Asthenia—Methotrexate—ankylosing spondylitis	0.000234	0.00157	CcSEcCtD
Vorinostat—Nausea—Prednisone—ankylosing spondylitis	0.000232	0.00156	CcSEcCtD
Vorinostat—Pruritus—Methotrexate—ankylosing spondylitis	0.000231	0.00155	CcSEcCtD
Vorinostat—HDAC8—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000227	0.00631	CbGpPWpGaD
Vorinostat—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000223	0.0015	CcSEcCtD
Vorinostat—NCOR1—Disease—B3GNT2—ankylosing spondylitis	0.000223	0.00619	CbGpPWpGaD
Vorinostat—Dizziness—Methotrexate—ankylosing spondylitis	0.000216	0.00145	CcSEcCtD
Vorinostat—Vomiting—Methotrexate—ankylosing spondylitis	0.000208	0.0014	CcSEcCtD
Vorinostat—HDAC2—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000206	0.00572	CbGpPWpGaD
Vorinostat—Headache—Methotrexate—ankylosing spondylitis	0.000204	0.00137	CcSEcCtD
Vorinostat—HDAC3—Metabolism—B3GNT2—ankylosing spondylitis	0.000203	0.00564	CbGpPWpGaD
Vorinostat—HDAC2—Disease—ANTXR2—ankylosing spondylitis	0.000199	0.00552	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000198	0.00551	CbGpPWpGaD
Vorinostat—Nausea—Methotrexate—ankylosing spondylitis	0.000194	0.0013	CcSEcCtD
Vorinostat—NCOR1—Metabolism—B3GNT2—ankylosing spondylitis	0.000187	0.00519	CbGpPWpGaD
Vorinostat—HDAC1—Disease—B3GNT2—ankylosing spondylitis	0.000182	0.00505	CbGpPWpGaD
Vorinostat—HDAC1—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000168	0.00467	CbGpPWpGaD
Vorinostat—HDAC11—Disease—HLA-A—ankylosing spondylitis	0.000167	0.00464	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000166	0.00462	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00015	0.00417	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—MMP3—ankylosing spondylitis	0.000141	0.00392	CbGpPWpGaD
Vorinostat—HDAC6—Disease—HLA-A—ankylosing spondylitis	0.00014	0.00389	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000139	0.00385	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00013	0.0036	CbGpPWpGaD
Vorinostat—HDAC4—Disease—HLA-A—ankylosing spondylitis	0.000126	0.00352	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—MMP3—ankylosing spondylitis	0.000118	0.00329	CbGpPWpGaD
Vorinostat—HDAC2—Disease—B3GNT2—ankylosing spondylitis	0.000117	0.00325	CbGpPWpGaD
Vorinostat—HDAC8—Disease—HLA-A—ankylosing spondylitis	0.000117	0.00325	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000116	0.00324	CbGpPWpGaD
Vorinostat—HDAC9—Disease—HLA-A—ankylosing spondylitis	0.000109	0.00304	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000107	0.00297	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—MMP3—ankylosing spondylitis	0.000107	0.00297	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—MMP3—ankylosing spondylitis	9.86e-05	0.00274	CbGpPWpGaD
Vorinostat—HDAC3—Disease—HLA-A—ankylosing spondylitis	9.81e-05	0.00273	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MMP3—ankylosing spondylitis	9.23e-05	0.00257	CbGpPWpGaD
Vorinostat—NCOR1—Disease—HLA-A—ankylosing spondylitis	9.01e-05	0.00251	CbGpPWpGaD
Vorinostat—HDAC3—Developmental Biology—TNF—ankylosing spondylitis	8.92e-05	0.00248	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.72e-05	0.00242	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MMP3—ankylosing spondylitis	8.29e-05	0.0023	CbGpPWpGaD
Vorinostat—NCOR1—Developmental Biology—TNF—ankylosing spondylitis	8.19e-05	0.00228	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MMP3—ankylosing spondylitis	7.62e-05	0.00212	CbGpPWpGaD
Vorinostat—HDAC1—Disease—HLA-A—ankylosing spondylitis	7.35e-05	0.00204	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MMP3—ankylosing spondylitis	6.21e-05	0.00173	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PTGER4—ankylosing spondylitis	5.62e-05	0.00156	CbGpPWpGaD
Vorinostat—HDAC2—Disease—HLA-A—ankylosing spondylitis	4.73e-05	0.00132	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MMP3—ankylosing spondylitis	4e-05	0.00111	CbGpPWpGaD
